Lastly, we used a therapeutic monoclonal antibody (mAb) (IC100) against the pyrin domain of ASC that has been shown to diminish pathological inflammasome activation in spinal cord injury [77], traumatic brain injury [78, 79], acute lung injury [80], multiple sclerosis [81], and inflammaging [40, 81]. The gene discussed is MEFV; the disease is multiple sclerosis.